^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ATG-101

i
Other names: Ori®Bs-001, YN051, ATN-101, ATG-101, PD-L1/4-1BB bispecific antibody, Ori-Bs-001
Associations
Trials
Company:
Antengene, Oricell
Drug class:
CD137 agonist, PD-L1 antagonist
Associations
Trials
4d
Radiolabelling and preclinical characterisation of [89Zr]Zr-Df-ATG-101 bispecific to PD-L1/4-1BB. (PubMed, Eur J Nucl Med Mol Imaging)
[89Zr]Zr-Df-ATG-101 in vivo distribution is dependent on PD-L1 expression in the MDA-MB-231 xenograft model. Immuno-PET with [89Zr]Zr-Df-ATG-101 provides real-time information about ATG-101 distribution and tumour uptake in vivo. Our data support the use of [89Zr]Zr-Df-ATG-101 to assess tumour and tissue uptake of ATG-101.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
ATG-101
3ms
Enrollment change • Metastases
|
ATG-101
12ms
The clinicopathological significance and potential function of ULK1 in colon cancer. (PubMed, Biotechnol Genet Eng Rev)
As a co-expressed gene (CEG), ATG101 was up-regulated in CC tissues and indicated poor survival. ULK1 is closely related to immune cells. ULK1 expression is upregulated in CC cells and upregulation of ULK1 may serve as an accurate prognostic factor, thereby providing novel intervention targets for therapy.
Journal
|
ATG-101
over1year
Partial Truncation of the C-Terminal Domain of PTCH1 in Cancer Enhances Autophagy and Metabolic Adaptability. (PubMed, Cancers (Basel))
Furthermore, the PTCH1 CTD mutant cells displayed increased proliferation in the presence of rapamycin and reduced sensitivity to glycolysis inhibitors. Our findings suggest that loss of the PTCH1-ATG101 interaction by mutations in the CTD of PTCH1 in cancer might confer a selective advantage by stimulating autophagy and facilitating adaptation to nutrient deprivation conditions.
Journal
|
PTCH1 (Patched 1)
|
PTCH1 mutation
|
sirolimus • ATG-101
over1year
ATG101-related signature predicts prognosis and therapeutic option in hepatocellular carcinoma. (PubMed, Sci Rep)
The ATS signature predicts the drug resistance to the immunotherapy, thus a combination of targeted therapy and immunotherapy might be suitable for ATS-high patients. This work shed light on the function of ATG101-related genes in HCC and revealed that the ATS signature may be a useful prognostic biomarker for differentiating molecular and immunological features and predicting probable response to the therapy.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
ATG-101
over1year
TRIMming down autophagy in breast cancer. (PubMed, Autophagy)
ULK1 plays an essential role in autophagy initiation through a complex formed with ATG13, RB1CC1/FIP200, and ATG101 in mammalian cells...We further demonstrate increased basal autophagy in trim27 knockout mice and establish physiological relevance in the context of breast cancer. Our study highlights the STK38L-TRIM27-ULK1 axis as a potential treatment avenue to explore for activating autophagy in various disease states.
Journal
|
RB1CC1 (RB1 Inducible Coiled-Coil 1)
|
ATG-101
3years
CircRAB11FIP1 promoted autophagy flux of ovarian cancer through DSC1 and miR-129. (PubMed, Cell Death Dis)
This study aimed to screen the expression profiles of circRNA, miRNA, and mRNA of ovarian cancer cells induced by Torin 1 (10 µM)...CircRAB11FIP1 bound to desmocollin 1to facilitate its interaction with ATG101...In general, this study demonstrated that circRAB11FIP1 regulated ATG7 and ATG14 by sponging miR-129. The data suggested that circRAB11FIP1 might serve as a candidate biomarker for EOC diagnosis and treatment.
Journal
|
ATG5 (Autophagy Related 5) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO)
|
ATG5 expression
|
Torin1 • ATG-101